CTI Life Sciences Fund III

CTI Life Sciences Fund III is a Canadian venture capital firm specializing in life sciences investments across North America and Europe. The firm focuses on innovative biotechnology companies at the pre-clinical and clinical development stages, aiming to catalyze emerging science and transform business objectives. Their mission is to invest in scalable companies that deliver impactful innovations and strong returns to stakeholders in the biotechnology and healthcare sectors.

The firm's investment strategy encompasses a broad range of stages, including pre-seed, seed, early stage, series A, series B, growth, late stage, and pre-IPO. Geographically, CTI Life Sciences Fund III targets investments in Canada, the United States, the United Kingdom, France, Spain, Switzerland, and Luxembourg. The firm has a diverse portfolio spanning various industries within the life sciences sector, such as biotechnology, healthcare, pharmaceuticals, medical devices, diagnostics, digital health, oncology, immunology, neurology, cardiology, rare diseases, infectious diseases, regenerative medicine, and genomics.

CTI Life Sciences Fund III has demonstrated a strong track record with over 20 successful investments, 10 exits, and 3 FDA approvals. Notable portfolio companies include DalCor Pharmaceuticals, Domain Therapeutics, Epitopea, Ability Pharmaceuticals, Thryv Therapeutics, Phenomic AI, Profound, and Oligon Therapeutics. The firm has also secured significant investments from partners like BDC Capital, Teralys Capital, and the Fonds de solidarité FTQ, reflecting confidence in its investment approach and the potential of its portfolio companies.